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Results
Myasthenia Gravis (MG) is an autoimmune disease of the 
neuromuscular junction. It is a rare disorder which causes muscle 
weakness and fatigue, and the typical treatment currently is 
anticholinesterase drugs, immunosuppressive drugs or surgery. One of 
the characteristics of MG is the early (< 50 years old) vs late (≥ 50 years 
old) onset. The onset is found to have been sex-specific, with early-
onset patients usually being females and late-onset patients usually 
being males (Gilhus, 2016). The purpose of this study was to analyze 
the biological pathways and key genetic contributors that lead to MG. 
In this study, we performed functional annotation of the significant 
variants from the results of an MG Genome-Wide Association (GWAS) 
study on a Southeastern European population. Furthermore, the three 
approaches used were positional mapping of the SNPs, pathway 
analysis, and eQTL mapping. From all three methods, we were able to 
detect five genes that were significantly associated with MG in the 
dataset including both early and late onset cases and 35 genes were 
detected from the early-onset dataset.
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In performing this study, we aimed to find significant genes and pathways which are 
associated with Myasthenia Gravis. To summarize, our major findings are the 36 genes that 
were found in the results of positional mapping, eQTL mapping, and MAGMA from the early-
onset and joint MG dataset; 35 were from the early-onset dataset and one unique gene was 
from the joint dataset. Additionally, the BioCarta Complement Pathway was found using 
MAGMA gene set-based analysis on the early-onset data. It is likely that these genes and 
pathways play some role in the development or progression of Myasthenia Gravis. In the next 
steps, we will perform a meta-analysis to determine whether our results overlap with 
previous MG studies and, if possible, to detect novel variants. Using these results we can 
progress our understanding of the disease. More specifically, further research into the 
THEMIS gene may prove useful as it is not located in the MHC region. Additionally, outside 
studies into the functions and mechanisms of the genes from our results may allow 
researchers to develop therapeutics and treatments which would delay the progression of the 
disease or lessen the symptoms. 
Conclusions
Methodology
Myasthenia Gravis (MG) is an autoimmune disease of the 
neuromuscular junction. The purpose of this study was to analyze the 
biological pathways and key genetic contributors that lead to MG. In 
this study, we performed functional annotation of the significant 
variants from the results of an MG Genome-Wide Association (GWAS) 
study on a Southeastern European population. Furthermore, the three 
approaches used were positional mapping of the SNPs, pathway 
analysis, and eQTL mapping. The positional and eQTL mapping were 
performed through FUMA. We annotated the SNPs to genes based on 
their physical position, and for the eQTL we used data from public 
repositories to test whether the expression of the gene is associated 
with allelic variation at the SNP. For the pathway analysis we used 
MAGMA; first, gene-analysis was performed in order to determine the 
p-value per gene based on whether the SNPs included in a gene were 
significantly associated with MG. Thirty-five genes were detected by all 
three approaches using the early-onset MG cases; all of them are 
located in the Major Histocompatibility Complex (MHC) region, which 
is reported to be associated with MG in previous studies. Five genes in 
the dataset including both early and late onset cases were detected by 
all three approaches, one being THEMIS and the other four are located 
in the MHC region. Overall, our study supports the results of previous 
studies as well as identifying novel risk factors. Further studies into the 
functions and mechanisms of these novel genes may allow researchers 
to develop therapeutics and treatments which would delay the 
progression of the disease or lessen the symptoms. 
Abstract
• Summary statistics data from in-house Myasthenia Gravis data set
• 43 MSigDB gene sets related to mechanisms in the development of 
MG and autoimmune disorders
• eQTL data from Blood eQTL Browser, BIOS QTL Browser 







• Chromatin interaction data from neural progenitor cells
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Figure 1: Schematic of Overall Research Approach
Figure 3: Venn Diagrams of overlapping results between 
eQTL mapping, positional mapping, and MAGMA methods
Figure 2: Manhattan plots of MAGMA results
Genes Found in All 3 Methods: 
N/A
Genes Found in All 3 Methods: APOM, 
ATF6B, ATP6V1G2, BAG6, C2, C6orf48, 
CDSN, CFB, CLIC1, CSNK2B, DDR1, 
DDX39B, GNL1, GTF2H4, HLA-B, HLA-
DQA1, HLA-DRA, MICA, MICB, MSH5, 
NCR3, NOTCH4, PPP1R18, PRRC2A, 
PSORS1C1, SFTA2, SLC44A4, STK19, 
TCF19, TNXB, TRIM10, TRIM15, 
TRIM26, TRIM31, VARS2
Genes Found in All 3 Methods: 
ATF6B, C2, MSH5, THEMIS, TNXB
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